Zaraket H, Hurt AC, Clinch B, Barr I, Lee N. Burden of influenza B virus infection and considerations for clinical management. Antiviral Res. 2020 Nov 4:104970
Influenza B viruses cause significant morbidity and mortality, particularly in children, but the awareness of their impact is often less than influenza A viruses partly due to their lack of pandemic potential. Here, we summarise the biology, epidemiology and disease burden of influenza B, and review existing data on available antivirals for its management. There has long been uncertainty surrounding the clinical efficacy of neuraminidase inhibitors (NAIs) for influenza B treatment. In this article, we bring together the existing data on NAIs and discuss these alongside recent large randomised controlled trial data for the new polymerase inhibitor baloxavir in high-risk influenza B patients. Finally, we offer considerations for the clinical management of influenza B, with a focus on children and high-risk patients where disease burden is highest.
See Also:
Latest articles in those days:
- Selected microwave irradiation effectively inactivates airborne avian influenza A(H5N1) virus 1 hours ago
- The Limited Role for Antiviral Therapy in Influenza 7 hours ago
- Pathogenesis of bovine H5N1 clade 2.3.4.4b infection in Macaques 8 hours ago
- [preprint]Susceptibility of bovine respiratory and mammary epithelial cells to avian and mammalian derived clade 2.3.4.4b H5N1 highly pathogenic avian influenza viruses 1 days ago
- Genetic Diversity of H10N3 Avian Influenza Virus Isolated from Anhui Province, China 1 days ago
[Go Top] [Close Window]